Aarey Drugs & Pharmaceuticals Reports Q1 Results: Revenue Dips, Profit Rises
Aarey Drugs & Pharmaceuticals released its Q1 FY26 unaudited financial results, showing a 19.48% decrease in total income to Rs. 1,037.60 lakhs. Despite lower revenue, profit after tax increased by 10.81% to Rs. 13.73 lakhs. Basic EPS improved by 9.09% to Rs. 0.48. The company maintained profitability despite revenue decline, suggesting effective cost management. The results were approved by the Board of Directors and reviewed by auditors.
*this image is generated using AI for illustrative purposes only.
Aarey Drugs & Pharmaceuticals , a manufacturer and trader of drugs and pharmaceuticals, has released its unaudited financial results for the first quarter. The company's performance shows a mixed picture with a decrease in revenue but an increase in profit compared to the same period last year.
Financial Highlights
| Particulars (in Rs. Lakhs) | Q1 FY26 | Q1 FY25 | YoY Change |
|---|---|---|---|
| Total Income | 1,037.60 | 1,288.71 | -19.48% |
| Total Expenses | 1,020.32 | 1,271.56 | -19.76% |
| Profit Before Tax | 17.28 | 17.31 | -0.17% |
| Profit After Tax | 13.73 | 12.39 | +10.81% |
| Basic EPS (in Rs.) | 0.48 | 0.44 | +9.09% |
Revenue and Profitability
Aarey Drugs & Pharmaceuticals reported a total income of Rs. 1,037.60 lakhs, marking a 19.48% decrease from Rs. 1,288.71 lakhs in the corresponding quarter of the previous year. Despite the revenue decline, the company managed to improve its profitability.
The profit after tax stood at Rs. 13.73 lakhs, showing a 10.81% increase from Rs. 12.39 lakhs in the same quarter last year. This improvement in profitability came despite a marginal decrease in profit before tax, which was Rs. 17.28 lakhs compared to Rs. 17.31 lakhs in the previous year's quarter.
Earnings Per Share
The company's basic earnings per share (EPS) improved to Rs. 0.48, up from Rs. 0.44 in the year-ago period, reflecting a 9.09% increase.
Operational Overview
Aarey Drugs & Pharmaceuticals operates in a single segment of manufacturing and trading of drugs and pharmaceuticals. The company's ability to maintain profitability despite lower revenue suggests effective cost management during the quarter.
Management Certification
The financial results were reviewed by the company's auditors, Motilal & Associates LLP. Managing Director Mihir R. Ghatalia and Chief Financial Officer Mira M. Ghatalia have certified the accuracy and compliance of the financial statements with applicable accounting standards and regulations.
Board Approval
The Board of Directors of Aarey Drugs & Pharmaceuticals Limited approved these unaudited financial results at their meeting. The meeting, which started at 4:00 p.m., concluded at 5:15 p.m.
As the pharmaceutical sector continues to evolve, Aarey Drugs & Pharmaceuticals' performance in the coming quarters will be closely watched by investors and industry analysts alike.
Historical Stock Returns for Aarey Drugs & Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.75% | +1.20% | +27.38% | +119.73% | +12.68% | +81.15% |
15
